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Abstract
With improvements in immunosuppressive therapy,
patient and graft survival in renal transplant recipients
have been prolonged. Increasing donor age and
patient survival rates have been related to an increase
in the number of de novo tumors. 
Posttransplant malignancy in these patients is an
important cause of graft loss and death in these
patients. Among cancers occurring after a kidney
transplant, renal cell carcinoma is the fifth most
common malignancy after lymphoproliferative dis -
orders, and skin, gastrointestinal, and lung cancers.
When nonmelanoma skin cancers and in situ carcinoma
of the cervix are excluded from malignancies, renal cell
carcinoma accounts for 2% of all cancers in the general
population, which increases to 5% in solid-organ
recipients. The majority of renal cell carcinomas found
in transplant recipients develop in the recipient’s
native kidneys, but only 9% of tumors develop in 
the allograft itself. Tumors transmitted by donors
represent only 0.02% to 0.2% of cases. Most de 
novo allograft renal cell carcinomas are single tumors.
The mechanisms of development of renal cell
carcinoma in renal grafts are not completely
understood.
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Introduction
A 59-year-old white man developed end-stage renal
disease in 1985 owing to IgA nephropathy. He had
been on long-term hemodialysis for 2 years and had
undergone a living-donor kidney transplant at 22
years of age. Induction immunosuppressive therapy
was anti-lymphocyte globulin, and the patient was
maintained on prednisone (10 mg every other day)
100 mg cyclosporine (twice daily), and 75 mg
azathioprine (once daily). No episodes of rejection
were noted. After transplant, the patient’s graft
function had been excellent, with a serum creatinine
level of 61.88 to 88.40 μmol/L. After 25 years of
uneventful follow-up, the patient developed
generalized edema and was hospitalized. At that time,
his serum creatinine was 353.60 μmol/L, and his serum
urea nitrogen level was13.57 μmol/L: a marked
proteinuria was reported (18 g/24 h). Doppler
ultrasounds of the graft were negative for vascular
problems and for the presence of renal masses. The
allograft appeared abnormally hyperechoic, with poor
corticomedullary differentiation. 
A renal biopsy was performed. By light
microscopy, the biopsy core showed cortical renal
tissue that contained 10 glomeruli, 1 of which had
advanced sclerosis; the remaining glomeruli showed
moderate mesangial expansion and focal duplication
of the glomerular basement membrane. There was
severe fibrous intimal arterial thickening with
duplication of the internal elastica and severe hyaline
arteriolosclerosis. Tubules showed moderate atrophy
associated with interstitial fibrosis and lymphocytic
infiltration without tubulitis. Proximal tubular
epithelium contained hyaline droplets. Tubules
contained hyaline casts and red cells. Direct
immunofluorescence on frozen sections revealed
granular deposits of IgA (+++), IgM (++), C3 (+),
kappa (+), and lambda (++) light chains in the
mesangium. C4d staining performed on frozen
sections was negative. These findings suggested 
a IgA nephropathy associated with chronic
glomerulopathy. Six months later, with a persistent
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status of poor renal function, a new echographic
control was performed. Three hypoechoic lesions in
different areas of the transplanted kidney were
observed. A computed tomography scan confirmed a
hypodense 3-cm lesion in the upper pole and 2
hypodense 1-cm lesions in the inferior pole. A renal
biopsy was performed on 1 of these lesions to
discriminate the diagnosis. A type 1 papillary renal
cell carcinoma was observed. The patient underwent
explantation of the allograft. The tumor was
confirmed on pathology (Figure 1). The patient's
postoperative course was uneventful, and at the time
of this writing, he is alive after 3 years, having
restarted substitutive therapy with hemodialysis.
Discussion
Renal cell carcinoma is the fifth most common
posttransplant malignancy. De novo malignancy of
the renal allograft is rare. Most de novo carcinomas
occur in the allograft from 2 to 213.5 months (average,
56 mo).1 Because of this low incidence, most
transplant units worldwide do not apply any specific
approach toward early detection of renal cell
carcinoma (RCCs) of kidney grafts. Carcinomas 
of the kidney grafts usually are diagnosed when
symptoms develop or incidentally, when an
ultrasound or a biopsy are done for another reason.2
The first-line diagnostic examination is an
ultrasound, which will disclose the presence of a
renal mass. Considering the insidious growth of
RCCs of the kidney graft, which often are diagnosed 
when they are large, as in our case, we believe that an
annual ultrasound of the kidney graft would detect
such tumors. Computed tomography or magnetic
resonance imaging usually is performed afterword
to confirm the diagnosis and give a more accurate
picture of the disease and its spreading. The
differential diagnosis includes RCC, lymphoma, and
infectious processes. The majority of RCCs of kidney
grafts have been treated by transplant removal and
discontinuation of immunosuppressive therapy.3,4
Good results can be obtained this way, because
radical nephrectomy achieves local control of the
disease, while discontinuation of immunosup-
pression allows the immune system to recover and
reject residual tumor cells.1 However, poor outcomes
also have been reported in patients dying of hepatic
metastases or febrile paraneoplastic syndrome soon
after transplant removal.4 A review of the current
literature identifies 4 cases of multicentric RCC.5,6
Recurrence of IgA nephropathy after kidney
transplant is common, while development of a tumor
on the allograft is anecdotal. However, to date, no
data exist in the literature regarding the presentation
of both pathologies after 25 years of follow-up.
Exclusion of recurrence also must be done after a
long time after the transplant. In these patients,
presence of de novo tumors must be excluded. A
multidisciplinary approach is required for kidney
transplant patients, in this way avoiding late and
potentially lethal diagnoses.7
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Figure 1. Hematoxylin and Eosin Stained Section of the Second Biopsy Shows
Papillary Cores With a Single Layer of Tumor Cells
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